Columbus<sup>®</sup> Proved Cost-effective by Health Economic Evaluation Report

Shanghai, China – The report "Health Economic Evaluation of Domestic and Imported Devices in the Treatment of Atrial Fibrillation," jointly conducted by Shanghai MicroPort EP MedTech Co., Ltd. ("MicroPort® EP") and Peking University Clinical Research Institute, was published in the national core periodical Medicine and Society (Issue 5, 2018).
 
This Health Economic Evaluation Report shows that Columbus® 3D EP Navigation System ("Columbus®") with its matching catheter is of better cost-effectiveness advantage compared to a similar imported product in the treatment of persistent atrial fibrillation. The report also suggests that relative government authorities can give preference to Columbus® and its matching catheter in centralized bidding and purchasing, as well as medical care reimbursement. Columbus® is the first domestically developed 3D EP navigation system that features real time electromagnetic device tracking with cardiac motion compensation. It is also the only domestically made 3D EP navigation system with the CE certificate, which has won high recognition from domestic experts for its outstanding performance.
 
This is the third health economic evaluation report published by MicroPort®. In 2015, MicroPort® released the health economic evaluation results of Firehawk® Rapamycin Target Eluting Coronary Stent System and WILLIS® Intracranial Stent Graft System.
 
Health economic evaluation plays an important role for decision makers to make healthcare policies and other related decisions. In China, health economic evaluation is also gaining higher recognition among government officials. As one of the first domestic medical device companies that started to conduct health economic evaluation, MicroPort® pays a special attention to the development of the health economic evaluation in China. In the future, MicroPort® will continue to provide more high-end medical devices and solutions by constant innovation.